☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
ivacaftor
Vertex Receives the Health Canada Marketing Authorization for Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat C...
April 21, 2022
Vertex's Kaftrio + Ivacaftor Receive the EC's Approval to Treat Cystic Fibrosis in People Aged 12 Years and Older
August 24, 2020
Vertex's Kalydeco (ivacaftor) Receives FDA's Approval for Cystic Fibrosis in Eligible Infants Aged 6 to Less than 12 Months
May 1, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.